Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight. One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss. This may affect strength and functional performance in people taking these medications. Resistance-training helps to offset loss of muscle mass during weight loss. Supplementation with creatine monohydrate is also effective for improving muscle mass and strength. The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance. The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks). It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Creatine | Experimental | 10 grams per day creatine |
|
| Placebo | Placebo Comparator | Placebo (maltodextrin) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dietary supplementation during a 12 week resistance-training program (creatine) | Dietary Supplement | creatine supplementation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in sit to stand performance (number of times) | change in number of times sitting and standing in 30 seconds | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in 10 meter gait speed (m/s) | change in walking speed over 10 meters | 12 weeks |
| Change in timed up and go (m/s) | change in time to stand up, walk 3m, turn, around, walk 3 m and sit down |
Not provided
Inclusion Criteria:
Exclusion Criteria:
All genders are eligible
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Philip D Chilibeck, PhD | Contact | 306-966-1072 | phil.chilibeck@usask.ca |
| Name | Affiliation | Role |
|---|---|---|
| Philip Chilibeck, PhD | University of Saskatchewan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Saskatchewan | Recruiting | Saskatoon | SK - Saskatchewan | S7N 5B2 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003401 | Creatine |
| ID | Term |
|---|---|
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D000596 | Amino Acids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Dietary supplementation during a 12 week resistance-training program (placebo) | Dietary Supplement | Placebo |
|
| 12 weeks |
| Change in lean tissue mass (kg) | Change in lean tissue mass as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in fat mass (kg) | Change in fat mass as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in whole body bone mineral density (g/cm squared) | Change in bone mineral density as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in femoral neck bone mineral density (g/cm squared) | Change in bone mineral density as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in total hip bone mineral density (g/cm squared) | Change in bone mineral density as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in lumbar spine bone mineral density (g/cm squared) | Change in bone mineral density as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in hip section modulus (cm-cubed) | Change in hip section modulus as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in muscle thickness of the biceps (cm) | Change in muscle thickness measured by ultrasound | 12 weeks |
| Change in muscle thickness of the quadriceps (cm) | Change in muscle thickness measured by ultrasound | 12 weeks |
| Change in bench press strength (kg) | change in upper body strength measured by predicted one repetition maximum | 12 weeks |
| Change in leg extension strength (kg) | Change in lower body strength measured by predicted one repetition maximum | 12 weeks |
| Change in hip buckling ratio (ratio) | Change in hip buckling ratio as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in hip cross-sectional area (cm-squared) | Change in hip cross-sectional area as determined by dual energy x-ray absorptiometry | 12 weeks |
| Change in hip cortical thickness (cm) | Change in hip cortical thickness as determined by dual energy x-ray absorptiometry | 12 weeks |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D000602 |
| Amino Acids, Peptides, and Proteins |